Osteoporosis and, as a consequence, osteoporotic fractures are highly prevalent, especially in postmenopausal women, and are often associated with serious health, social, and economic consequences.
- As a primary care physician, what contribution can I make to better care for patients with osteoporosis?
- How can I recognize and treat osteoporosis in time in my practice?
- What does long-term management look like?
Get the answers to these questions in the latest CME video, “Osteoporosis in Motion.”
Moderation:
Romeo Providoli, MD
Cabinet Dr. Romeo Providoli, Sierre
Board of Directors SGAIM
Intro
KD Diana Frey, MD
Senior Physician Clinic for Rheumatology
University Hospital Zurich
Prof. Dr. med. Serge Ferrari
Head of the Department of Bone Diseases
Geneva University Hospital
President of the Swiss Association against Osteoporosis
Prof. Dr. med. Christian Meier
Senior Physician Endocrinology, Diabetology and Metabolism
University Hospital Basel
Outro
|
For many years, Amgen Switzerland AG has been committed to the field of osteoporosis. This commitment goes far beyond the marketing of the osteoporosis drug. Prolia® drug: For example, Amgen supports the new Therapy Support Program LOOP LOOP program, which supports both physicians and patients during treatment with Prolia®. Amgen is also committed to conducting studies in Switzerland and fostering collaboration with professional societies. For example you can learn here in a Video interview with Prof. Burckhardt more about a new Swiss real-world study or you can find out about the current Recommendations of the SVGO inform yourself. If you are interested in further such practice-relevant content, please register here for the Amgen Info Service newsletter! |
